These proteins have been produced in different hosts and are being investigated for development of a successful dengue vaccine. The promising subunit vaccines are mainly based on envelope or its domain and non-structural proteins of dengue virus. These candidates are at different stages of vaccine development and have their own merits and demerits. As the only licensed dengue vaccine (Dengvaxia) is unable to confer balanced protection against all the serotypes, therefore various approaches for development of dengue vaccines including tetravalent live attenuated, inactivated, plasmid DNA, virus-vectored, virus-like particles, and recombinant subunit vaccines are being explored. Dengue virus is a single stranded RNA virus encoding three structural proteins (capsid protein, pre-membrane protein, and envelope protein) and seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5). Dengue is an emerging viral disease caused by any of dengue virus 1–4 serotypes that affects the human population around the globe. Therefore, efficacious vaccines are needed to control the spread of dengue worldwide. Since there is no specific antiviral therapy available against dengue, the prevention by vaccination is the mainstay in reducing the disease burden. Various recombinant proteins of therapeutic and prophylactic importance have been successfully produced in microbial and higher expression host systems. Recombinant proteins are gaining enormous importance these days due to their wide application as biopharmaceutical products and proven safety record.
0 Comments
Leave a Reply. |